Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics
company, and The Medicines Company (Nasdaq:MDCO), a global
biopharmaceutical company focusing on saving lives, alleviating
suffering and contributing to the economics of healthcare by focusing on
the world’s leading acute/intensive care hospitals, announced today that
Alnylam has filed a Clinical Trial Application (CTA) with the U.K.
Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a
Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the
treatment of hypercholesterolemia.
for Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks